State Street Journal’s Post

🚀 𝐏𝐟𝐢𝐳𝐞𝐫’𝐬 𝐐𝟑 𝐄𝐚𝐫𝐧𝐢𝐧𝐠𝐬 𝐊𝐧𝐨𝐜𝐤𝐨𝐮𝐭: 𝐒𝐭𝐫𝐨𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬, 𝐈𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐢𝐥𝐥 𝐒𝐤𝐞𝐩𝐭𝐢𝐜𝐚𝐥 ? Pfizer just delivered a stunning Q3 performance, smashing analysts' expectations with revenues up 32% YoY and earnings per share (EPS) at $1.06 – far exceeding Wall Street's estimates. Yet, despite these positive numbers, Pfizer's stock fell 2% as investor concerns linger. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 💉 𝐂𝐎𝐕𝐈𝐃 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐒𝐩𝐢𝐤𝐞: COVID products Comirnaty and Paxlovid provided a major revenue boost, helping Pfizer revise its 2024 forecast up to $61B-$64B. This increase comes as governments continue to stockpile treatments. 📉 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧 𝐂𝐨𝐫𝐞 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬: Outside of COVID, core segments showed mixed results: Primary Care saw some declines, impacted by IRA price controls on Eliquis. Oncology assets from Seagen showed limited returns despite a $43B acquisition. Specialty Care had bright spots like Vyndaqel, up 60% YoY, but other drugs, like Xeljanz, faced declines. 💸 𝐌&𝐀 𝐚𝐧𝐝 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞: Pfizer’s recent M&A spree ($70B+ in acquisitions) hasn’t generated blockbuster returns as hoped, raising questions about long-term growth. Key pipeline prospects include an obesity drug and promising assets in oncology and immunology. 💰 𝐃𝐢𝐯𝐢𝐝𝐞𝐧𝐝 𝐀𝐩𝐩𝐞𝐚𝐥: Pfizer still offers a strong 5.8% dividend yield and trades at one of the lowest valuations in Big Pharma – a silver lining for income-seeking investors. 𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐀𝐡𝐞𝐚𝐝 Pfizer remains the third largest Pharma by revenue in the U.S., with assets that could surprise in 2025. Though challenges persist, COVID-related boosts and strategic assets hold potential for future gains. 𝐁𝐨𝐭𝐭𝐨𝐦 𝐋𝐢𝐧𝐞: Pfizer’s Q3 results were impressive, but the market’s cautious reaction reflects longer-term uncertainties. With activist investors stepping in, change may be on the horizon. 💼 #Pharma #Pfizer #Earnings #HealthcareInvesting #LifeSciences #BusinessUpdates

"Whether the entrenched innovators and corporate giants of old or those quickly accelerating up the ranks, each, in their own way, is navigating today’s new and unique mix of issues and barriers—be it on the policy front (#Inflation Reduction Act, #pricing scrutiny); economic (#patent expirations/#biosimilar competition),operational (supply chain disruption, global unrest), or #regulatory (digital disruption, #compliance), to name a few. In turn, they are responding with various strategic decisions and actions, ranging from consolidations and layoffs, to pipeline reprioritization and brand expansion, to M&A and product licensing pursuits." #pharma #pharmaceutical #ranking #innovation #supplychain #digital

📢 Breaking News: Pfizer Announces New $1.5 Billion Cost-Cutting Initiative 📢 In a strategic move to optimize operations, Pfizer has announced an additional $1.5 billion in cost reductions, adding to its already robust $4 billion savings plan initiated last year. This latest phase underscores Pfizer's commitment to streamlining its manufacturing base and increasing productivity amid a post-pandemic business recalibration. 🔍 Key Highlights: Targeted Reductions: Focus on enhancing operational efficiencies and simplifying processes within Pfizer Global Supply. Multi-Phased Approach: This is just the first step in a series of planned cost-saving measures to be rolled out over the coming years. Financial Impact: The initial phase aims to deliver $1.5 billion in annual savings by the end of 2027, with significant one-time costs anticipated in 2024. 💡 Insight for Pharma Executives: As the pharmaceutical landscape continues to evolve, Pfizer's proactive measures highlight the importance of agility and efficiency. These cost-cutting strategies are not merely about savings but about positioning the company for sustained growth and resilience in a competitive market. 👉 Discussion Point: How are other pharmaceutical giants that surged during the pandemic, like Moderna, adapting their operations post-pandemic? Separately, once rising star Cue Health is closing operations. Share your insights and strategies for navigating this dynamic environment. Stay informed with MedicineToMarket.com for more updates and in-depth analyses on industry movements. #PharmaNews #Pfizer #CostCutting #PharmaceuticalIndustry #MedicineToMarket #OperationalEfficiency #BusinessStrategy

What's New to TheStreet... 💊 Activist Investor Starboard Value Takes $1 Billion Stake in Pfizer 💼 As Pfizer faces slumping shares due to slowing demand for Covid-19 vaccines and treatments, activist investor Starboard Value has stepped in, taking a $1 billion stake in the drugmaker. This move signals confidence in Pfizer’s potential for a turnaround and future growth. How do you think Starboard’s investment will shape Pfizer’s next chapter? Share below!💬⬇️ 👉🏻Follow New To The Street for more! #pfizer #starboardvalue #pharmanews #investing #pharma #stocks #financialnews #innovation #businessupdate #businessnews #business #news #newtothestreet

In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.

📊 Big Pharma's $383B War Chest: Who's Ready for the Patent Cliff? Morgan Stanley's latest report reveals a seismic shift in the pharma landscape: • $183.5B in annual sales at risk due to patent expirations by 2030 • $383.1B in "firepower" available for strategic M&A moves Winners and Losers: 🏆 Well-positioned companies (% of revenue at risk): • Vertex (6%) • Gilead (24%) • AbbVie (29%) • Eli Lilly (31%) • Pfizer (33%) • J&J (33%) - beating the 38% industry average ⚠️ Most exposed: • Amgen (67%) - Top 4 products, including Prolia and Xgeva, facing patent cliffs • Bristol Myers Squibb • Merck With billions at stake and a massive war chest, how will Big Pharma navigate these choppy waters? Will we see a surge in acquisitions to fill pipeline gaps? What's your take: Which companies are best positioned to weather the storm, and who needs to make big moves? #Pharma #Biotech #PatentCliff #mergersandacquisitions https://lnkd.in/eBtUgKhA

📢 GSK 𝐚𝐧𝐝 Pfizer 𝐂𝐄𝐎 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 ⭕ The most recent example highlights the 𝐂𝐄𝐎'𝐬 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐟𝐨𝐫 𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐲'𝐬 𝐠𝐫𝐨𝐰𝐭𝐡, which in turn dictates their personal growth trajectory. ⭕ In FY 2023, Pfizer experienced a staggering 41% 𝐝𝐞𝐜𝐥𝐢𝐧𝐞 𝐢𝐧 𝐫𝐞𝐯𝐞𝐧𝐮𝐞, while GSK saw a successful year with a 5% 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐫𝐞𝐯𝐞𝐧𝐮𝐞. ⭕ The 𝐢𝐦𝐩𝐚𝐜𝐭 of these contrasting performances was also 𝐫𝐞𝐟𝐥𝐞𝐜𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐞𝐧𝐬𝐚𝐭𝐢𝐨𝐧 of the respective CEOs. 🔸 𝐆𝐒𝐊'𝐬 𝐂𝐄𝐎 saw a remarkable 51% 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 in pay 🔸Whereas, 𝐏𝐟𝐢𝐳𝐞𝐫'𝐬 𝐂𝐄𝐎 faced a 35% 𝐩𝐚𝐲 𝐜𝐮𝐭 ⚠ 𝘛𝘩𝘪𝘴 𝘤𝘰𝘮𝘱𝘢𝘳𝘪𝘴𝘰𝘯 𝘶𝘯𝘥𝘦𝘳𝘴𝘤𝘰𝘳𝘦𝘴 𝘵𝘩𝘦 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 𝘭𝘪𝘯𝘬 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 CEO 𝘱𝘦𝘳𝘧𝘰𝘳𝘮𝘢𝘯𝘤𝘦, 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘨𝘳𝘰𝘸𝘵𝘩, 𝘢𝘯𝘥 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴.

What's New to TheStreet... 💊 Activist Investor Starboard Value Takes $1 Billion Stake in Pfizer 💼 As Pfizer faces slumping shares due to slowing demand for Covid-19 vaccines and treatments, activist investor Starboard Value has stepped in, taking a $1 billion stake in the drugmaker. This move signals confidence in Pfizer’s potential for a turnaround and future growth. How do you think Starboard’s investment will shape Pfizer’s next chapter? Share below!💬⬇️ 👉🏻Follow New To The Street for more! #pfizer #starboardvalue #pharmanews #investing #pharma #stocks #financialnews #innovation #businessupdate #businessnews #business #news #newtothestreet

Thoughts on this? >> Pfizer ups 2024 guidance by $1B after multiple rounds of cost cuts >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

When businesses focus on customers and team members first, they create sustainable products and services. Organizations that focus on the rise and fall of humans' buying and selling prices of a stock, purporting to maintain 'shareholder value', are breaking the flow of real advancement. Pfizer will continue to rise profitably and pump out passive income for the very long term, if opposing interests stay out and let them do their long term job. Pfizer #pfizer #health #healthcare #investment #business #profit #passiveincome #growth #cashflow https://lnkd.in/e4jAk3MD